semaglutide mastery course
Unit 7 of 12
kidney disease and liver outcomes
FLOW trial results, eGFR trajectories, and emerging MASH evidence
kidney disease and liver outcomes
The FLOW trial established semaglutide as the first GLP-1 receptor agonist to demonstrate kidney-specific benefits in patients with type 2 diabetes and chronic kidney disease. This unit covers the primary and secondary renal endpoints, eGFR slope changes, and the parallel evidence accumulating for MASH and liver fibrosis resolution.
The paid sections walk through FLOW's 24% composite kidney endpoint reduction, the mechanisms behind eGFR slope preservation, and why the phase 2 MASH resolution data led to Wegovy's August 2025 accelerated approval for liver disease.
Interactive Visualization
explore kidney function trajectories and outcome event curves from the FLOW trial.
FLOW trial kidney function curves
3,533
adults with T2D and CKD enrolled in FLOW -- the first dedicated GLP-1RA kidney outcomes trial, stopped early for efficacy
24%
reduction in composite kidney endpoint (HR 0.76; 95% CI 0.66-0.88) -- sustained eGFR decline, ESKD, or kidney-related death
1.16
ml/min/year slower eGFR decline with semaglutide vs placebo -- translating to years of preserved kidney function over time
59%
MASH resolution rate without worsening fibrosis at the 0.4 mg daily dose (phase 2 trial, vs 17% placebo)
trial-stopped-early signal. FLOW was halted by the data monitoring committee for clear efficacy -- one of the strongest signals in clinical research. however, MASH evidence remains at the accelerated-approval stage (August 2025), meaning confirmatory outcomes trials are still required to verify that histological improvement translates to reduced clinical liver events.
key terms for this unit
E
The primary measure of kidney function, calculated from serum creatinine, age, sex, and race. Normal is above 90 ml/min/1.73m2. FLOW enrolled patients with eGFR 25-75 and showed semaglutide slowed decline by 1.16 ml/min/year versus placebo.
U
A measure of albumin leaking into urine, indicating kidney damage. FLOW required UACR of 100-5,000 mg/g for enrollment. Elevated UACR is both a marker of kidney injury and a predictor of cardiovascular risk in diabetic populations.
M
Formerly called NASH. A progressive liver disease with fat accumulation, inflammation, and hepatocyte ballooning. Semaglutide achieved 59% resolution without worsening fibrosis in phase 2 trials, leading to FDA accelerated approval in August 2025 for MASH with F2-F3 fibrosis.
D
The synthesis of new fatty acids from non-lipid precursors like fructose and glucose. Insulin resistance drives excess DNL in the liver, contributing to hepatic fat accumulation. Semaglutide reduces DNL indirectly by improving insulin sensitivity through weight loss.
S
Sodium-glucose cotransporter 2 inhibitors (e.g., empagliflozin, dapagliflozin) with proven renal and cardiovascular outcomes. Most FLOW patients were already on SGLT2i at baseline, meaning semaglutide provided additive kidney protection on top of the existing standard of care.